Platelet-Rich Plasma as an Autologous and Proangiogenic Cell Delivery System
Jessica Zahn, Markus Loibl, Christoph Sprecher, Michael Nerlich, Mauro Alini, Sophie Verrier, Marietta Herrmann, Jessica Zahn, Markus Loibl, Christoph Sprecher, Michael Nerlich, Mauro Alini, Sophie Verrier, Marietta Herrmann
Abstract
Angiogenesis is a key factor in early stages of wound healing and is crucial for the repair of vascularized tissues such as the bone. However, supporting timely revascularization of the defect site still presents a clinical challenge. Tissue engineering approaches delivering endothelial cells or prevascularized constructs may overcome this problem. In the current study, we investigated platelet-rich plasma (PRP) gels as autologous, injectable cell delivery systems for prevascularized constructs. PRP was produced from human thrombocyte concentrates. GFP-expressing human umbilical vein endothelial cells (HUVECs) and human bone marrow-derived mesenchymal stem cells (MSCs) were encapsulated in PRP gels in different proportions. The formation of cellular networks was assessed over 14 days by time-lapse microscopy, gene expression analysis, and immunohistology. PRP gels presented a favorable environment for the formation of a three-dimensional (3D) cellular network. The formation of these networks was apparent as early as 3 days after seeding. Networks increased in complexity and branching over time but were only stable in HUVEC-MSC cocultures. The high cell viability together with the 3D capillary-like networks observed at early time points suggests that PRP can be used as an autologous and proangiogenic cell delivery system for the repair of vascularized tissues such as the bone.
Figures
References
- Carano R. A. D., Filvaroff E. H. Angiogenesis and bone repair. Drug Discovery Today. 2003;8:980–989.
- Johnson E. O., Troupis T., Soucacos P. N. Tissue-engineered vascularized bone grafts: basic science and clinical relevance to trauma and reconstructive microsurgery. Microsurgery. 2011;31:176–182. doi: 10.1002/micr.20821.
- Laschke M. W., Menger M. D. Vascularization in tissue engineering: angiogenesis versus inosculation. European Surgical Research. 2012;48:85–92. doi: 10.1159/000336876.
- Auger F. A., Gibot L., Lacroix D. The pivotal role of vascularization in tissue engineering. In: Yarmush M. L., editor. Annual Review of Biomedical Engineering. Vol. 15. Palo Alto: Annual Reviews; 2013. pp. 177–200.
- Laschke M. W., Harder Y., Amon M., et al. Angiogenesis in tissue engineering: breathing life into constructed tissue substitutes. Tissue Engineering. 2006;12:2093–2104. doi: 10.1089/ten.2006.12.2093.
- Tremblay P. L., Hudon V., Berthod F., Germain L., Auger F. A. Inosculation of tissue-engineered capillaries with the host’s vasculature in a reconstructed skin transplanted on mice. American Journal of Transplantation. 2005;5:1002–1010. doi: 10.1111/j.1600-6143.2005.00790.x.
- Laschke M. W., Vollmar B., Menger M. D. Inosculation: connecting the life-sustaining pipelines. Tissue Engineering Part B, Reviews. 2009;15:455–465. doi: 10.1089/ten.TEB.2009.0252.
- Laschke M. W., Menger M. D. Prevascularization in tissue engineering: current concepts and future directions. Biotechnology Advances. 2016;34:112–121. doi: 10.1016/j.biotechadv.2015.12.004.
- Rouwkema J., de Boer J., Van Blitterswijk C. A. Endothelial cells assemble into a 3-dimensional prevascular network in a bone tissue engineering construct. Tissue Engineering. 2006;12:2685–2693. doi: 10.1089/ten.2006.12.2685.
- Tsigkou O., Pomerantseva I., Spencer J. A., et al. Engineered vascularized bone grafts. Proceedings of the National Academy of Sciences of the United States of America. 2010;107:3311–3316. doi: 10.1073/pnas.0905445107.
- Ren L. L., Ma D. Y., Liu B., et al. Preparation of three-dimensional vascularized MSC cell sheet constructs for tissue regeneration. BioMed Research International. 2014;2014:10. doi: 10.1155/2014/301279.301279
- Freeman F. E., Allen A. B., Stevens H. Y., Guldberg R. E., McNamara L. M. Effects of in vitro endochondral priming and pre-vascularisation of human MSC cellular aggregates in vivo. Stem Cell Research & Therapy. 2015;6:p. 218. doi: 10.1186/s13287-015-0210-2.
- Chen X., Aledia A. S., Popson S. A., Him L., Hughes C. C., George S. C. Rapid anastomosis of endothelial progenitor cell-derived vessels with host vasculature is promoted by a high density of cotransplanted fibroblasts. Tissue Engineering Part A. 2010;16:585–594. doi: 10.1089/ten.TEA.2009.0491.
- Pang H., Wu X. H., Fu S. L., et al. Prevascularisation with endothelial progenitor cells improved restoration of the architectural and functional properties of newly formed bone for bone reconstruction. International Orthopaedics. 2013;37:753–759. doi: 10.1007/s00264-012-1751-y.
- Herrmann M., Binder A., Menzel U., Zeiter S., Alini M., Verrier S. CD34/CD133 enriched bone marrow progenitor cells promote neovascularization of tissue engineered constructs in vivo. Stem Cell Research. 2014;13:465–477. doi: 10.1016/j.scr.2014.10.005.
- Frueh F. S., Spater T., Lindenblatt N., et al. Adipose tissue-derived microvascular fragments improve vascularization, lymphangiogenesis, and integration of dermal skin substitutes. The Journal of Investigative Dermatology. 2017;137:217–227.
- Groppa E., Brkic S., Bovo E., et al. VEGF dose regulates vascular stabilization through semaphorin3A and the neuropilin-1(+) monocyte/TGF-1 paracrine axis. EMBO Molecular Medicine. 2015;7:1366–1384.
- Senzel L., Gnatenko D. V., Bahou W. F. The platelet proteome. Current Opinion in Hematology. 2009;16:329–333.
- Zahedi R. P., Lewandrowski U., Wiesner J., et al. Phosphoproteome of resting human platelets. Journal of Proteome Research. 2008;7:526–534.
- Ferrari M., Zia S., Valbonesi M., et al. A new technique for hemodilution, preparation of autologous platelet-rich plasma and intraoperative blood salvage in cardiac-surgery. The International Journal of Artificial Organs. 1987;10:47–50.
- Thushara R. M., Hemshekhar M., Basappa, Kemparaju K., Rangappa K. S., Girish K. S. Biologicals, platelet apoptosis and human diseases: an outlook. Critical Reviews in Oncology/Hematology. 2015;93:149–158. doi: 10.1016/j.critrevonc.2014.11.002.
- Lippross S., Loibl M., Hoppe S., et al. Platelet released growth factors boost expansion of bone marrow derived CD34(+) and CD133(+) endothelial progenitor cells for autologous grafting. Platelets. 2011;22:422–432.
- Duttenhoefer F., Lara de Freitas R., Meury T., et al. 3D scaffolds co-seeded with human endothelial progenitor and mesenchymal stem cells: evidence of prevascularisation within 7 days. European Cells & Materials. 2013;26:49–64. discussion -5.
- Marx R. E. Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dentistry. 2001;10:225–228.
- Cavallo C., Filardo G., Mariani E., et al. Comparison of platelet-rich plasma formulations for cartilage healing: an in vitro study. The Journal of Bone and Joint Surgery American. 2014;96:423–429.
- Xie X., Zhang C., Tuan R. S. Biology of platelet-rich plasma and its clinical application in cartilage repair. Arthritis Research & Therapy. 2014;16:p. 204.
- Andriolo L., Di Matteo B., Kon E., Filardo G., Venieri G., Marcacci M. PRP augmentation for ACL reconstruction. BioMed Research International. 2015;2015:15. doi: 10.1155/2015/371746.371746
- Braun H. J., Wasterlain A. S., Dragoo J. L. The use of PRP in ligament and meniscal healing. Sports Medicine and Arthroscopy Review. 2013;21:206–212. doi: 10.1097/JSA.0000000000000005.
- Di Matteo B., Loibl M., Andriolo L., et al. Biologic agents for anterior cruciate ligament healing: a systematic review. World Journal of Orthopedics. 2016;7:592–603.
- Kaux J. F., Drion P. V., Colige A., et al. Effects of platelet-rich plasma (PRP) on the healing of Achilles tendons of rats. Wound Repair and Regeneration. 2012;20:748–756.
- Filardo G., Kon E., Di Matteo B., et al. Platelet-rich plasma injections for the treatment of refractory Achilles tendinopathy: results at 4 years. Blood Transfusion. 2014;12:533–540. doi: 10.2450/2014.0289-13.
- Rowden A., Dominici P., D'Orazio J., et al. Double-blind, randomized, placebo-controlled study evaluating the use of platelet-rich plasma therapy (PRP) for acute ankle sprains in the emergency department. The Journal of Emergency Medicine. 2015;49:546–551.
- Jalowiec J. M., D'Este M., Bara J. J., et al. An in vitro investigation of platelet-rich plasma-gel as a cell and growth factor delivery vehicle for tissue engineering. Tissue Engineering Part C, Methods. 2016;22:49–58.
- Loibl M., Lang S., Brockhoff G., et al. The effect of leukocyte-reduced platelet-rich plasma on the proliferation of autologous adipose-tissue derived mesenchymal stem cells. Clinical Hemorheology and Microcirculation. 2016;61:599–614.
- Loibl M., Lang S., Hanke A., et al. Leukocyte-reduced platelet-rich plasma alters protein expression of adipose tissue-derived mesenchymal stem cells. Plastic and Reconstructive Surgery. 2016;138:397–208.
- Martinez C. E., Gonzalez S. A., Palma V., Smith P. C. Platelet-poor and platelet-rich plasma stimulate bone lineage differentiation in periodontal ligament stem cells. Journal of Periodontology. 2016;87:E18–E26.
- Gobbi G., Vitale M. Platelet-rich plasma preparations for biological therapy: applications and limits. Operative Techniques in Orthopaedics. 2012;22:10–15.
- Dohan Ehrenfest D. M., Andia I., Zumstein M. A., Zhang C.-Q., Pinto N. R., Bielecki T. Classification of platelet concentrates (platelet-rich plasma-PRP, platelet-rich fibrin-PRF) for topical and infiltrative use in orthopedic and sports medicine: current consensus, clinical implications and perspectives. Muscles, Ligaments and Tendons Journal. 2014;4:3–9.
- Mautner K., Malanga G. A., Smith J., et al. A call for a standard classification system for future biologic research: the rationale for new PRP nomenclature. PM & R. 2015;7:S53–S59. doi: 10.1016/j.pmrj.2015.02.005.
- Lubkowska A., Dolegowska B., Banfi G. Growth factor content in PRP and their applicability in medicine. Journal of Biological Regulators and Homeostatic Agents. 2012;26:3S–22S.
- Boswell S. G., Schnabel L. V., Mohammed H. O., Sundman E. A., Minas T., Fortier L. A. Increasing platelet concentrations in leukocyte-reduced platelet-rich plasma decrease collagen gene synthesis in tendons. The American Journal of Sports Medicine. 2014;42:42–49.
- Mazzocca A. D., McCarthy M. B. R., Chowaniec D. M., et al. The positive effects of different platelet-rich plasma methods on human muscle, bone, and tendon cells. The American Journal of Sports Medicine. 2012;40:1742–1749.
- Sundman E. A., Cole B. J., Karas V., et al. The anti-inflammatory and matrix restorative mechanisms of platelet-rich plasma in osteoarthritis. The American Journal of Sports Medicine. 2014;42:35–41.
- Kurita J., Miyamoto M., Ishii Y., et al. Enhanced vascularization by controlled release of platelet-rich plasma impregnated in biodegradable gelatin hydrogel. The Annals of Thoracic Surgery. 2011;92:837–844. discussion 44.
- Zahn J., Herrmann M., Loibl M., Alini M., Verrier S. Platelet-rich plasma as autologous cell delivery and pro-angiogenic hydrogel for bone tissue engineering. Bone & Joint Journal. 2017;99-B(Supplement 2):p. 87.
- Herrmann M., Bara J. J., Sprecher C. M., et al. Pericyte plasticity - comparative investigation of the angiogenic and multilineage potential of pericytes from different human tissues. European Cells & Materials. 2016;31:236–249.
- Takebe T., Enomura M., Yoshizawa E., et al. Vascularized and complex organ buds from diverse tissues via mesenchymal cell-driven condensation. Cell Stem Cell. 2015;16:556–565.
- Ma J. L., Yang F., Both S. K., et al. In vitro and in vivo angiogenic capacity of BM-MSCs/HUVECs and AT-MSCs/HUVECs cocultures. Biofabrication. 2014;6:p. 10.
- Reginato S., Gianni-Barrera R., Banfi A. Taming of the wild vessel: promoting vessel stabilization for safe therapeutic angiogenesis. Biochemical Society Transactions. 2011;39:1654–1658.
- Armulik A., Genove G., Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Developmental Cell. 2011;21:193–215.
- Loibl M., Binder A., Herrmann M., et al. Direct cell-cell contact between mesenchymal stem cells and endothelial progenitor cells induces a pericyte-like phenotype in vitro. BioMed Research International. 2014;2014:10. doi: 10.1155/2014/395781.395781
- Goerke S. M., Plaha J., Hager S., et al. Human endothelial progenitor cells induce extracellular signal-regulated kinase-dependent differentiation of mesenchymal stem cells into smooth muscle cells upon cocultivation. Tissue Engineering Part A. 2012;18:2395–2405.
- Au P., Tam J., Fukumura D., Jain R. K. Bone marrow-derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature. Blood. 2008;111:4551–4558.
- Li Q., Yu Y., Bischoff J., Mulliken J. B., Olsen B. R. Differential expression of CD146 in tissues and endothelial cells derived from infantile haemangioma and normal human skin. The Journal of Pathology. 2003;201:296–302.
- Covas D. T., Panepucci R. A., Fontes A. M., et al. Multipotent mesenchymal stromal cells obtained from diverse human tissues share functional properties and gene-expression profile with CD146(+) perivascular cells and fibroblasts. Experimental Hematology. 2008;36:642–654.
- Huang F. J., You W. K., Bonaldo P., Seyfried T. N., Pasquale E. B., Stallcup W. B. Pericyte deficiencies lead to aberrant tumor vascularizaton in the brain of the NG2 null mouse. Developmental Biology. 2010;344:1035–1046.
- Nehls V., Drenckhahn D. The versatility of microvascular pericytes - from mesenchyme to smooth-muscle. Histochemistry. 1993;99:1–12.
- Winkler E. A., Bell R. D., Zlokovic B. V. Pericyte-specific expression of PDGF beta receptor in mouse models with normal and deficient PDGF beta receptor signaling. Molecular Neurodegeneration. 2010;5:p. 11.
- Diaz-Flores L., Gutierrez R., Madrid J. F., et al. Pericytes. Morphofunction, interactions and pathology in a quiescent and activated mesenchymal cell niche. Histology and Histopathology. 2009;24:909–969. doi: 10.14670/HH-24.909.
- Armulik A., Abramsson A., Betsholtz C. Endothelial/pericyte interactions. Circulation Research. 2005;97:512–523. doi: 10.1161/01.RES.0000182903.16652.d7.
- Hermansson M., Nister M., Betsholtz C., Heldin C. H., Westermark B., Funa K. Endothelial-cell hyperplasia in human glioblastoma - coexpression of messenger RNA for platelet-derived growth-factor (PDGF) b-cain and PDGF receptor suggests autocrine growth-stimulation. Proceedings of the National Academy of Sciences of the United States of America. 1988;85:7748–7752.
- Plate K. H., Breier G., Farrell C. L., Risau W. Platelet-derived growth factor receptor-beta is induced during tumor-development and up-regulated during tumor progression in endothelial-cells in human gliomas. Laboratory Investigation. 1992;67:529–534.
- von Ballmoos M. W., Yang Z. J., Volzmann J., Baumgartner I., Kalka C., Di Santo S. Endothelial progenitor cells induce a phenotype shift in differentiated endothelial cells towards PDGF/PDGFR beta axis-mediated angiogenesis. PLoS One. 2010;5:p. 10.
- Hawighorst T., Skobe M., Streit M., et al. Activation of the Tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth. The American Journal of Pathology. 2002;160:1381–1392.
- Fagiani E., Christofori G. Angiopoietins in angiogenesis. Cancer Letters. 2013;328:18–26.
- Maisonpierre P. C., Suri C., Jones P. F., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277:55–60.
- Benjamin L. E., Hemo I., Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development. 1998;125:1591–1598.
- Benjamin L. E., Golijanin D., Itin A., Pode D., Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. The Journal of Clinical Investigation. 1999;103:159–165.
- Villars F., Guillotin B., Amedee T., et al. Effect of HUVEC on human osteoprogenitor cell differentiation needs heterotypic gap junction communication. American Journal of Physiology Cell Physiology. 2002;282:C775–C785.
- Wang D. G., Zhang F. X., Chen M. L., Zhu H. J., Yang B., Cao K. J. Cx43 in mesenchymal stem cells promotes angiogenesis of the infarcted heart independent of gap junctions. Molecular Medicine Reports. 2014;9:1095–1102. doi: 10.3892/mmr.2014.1923.
- Loibl M., Lang S., Dendl L. M., et al. Leukocyte-reduced platelet-rich plasma treatment of basal thumb arthritis: a pilot study. BioMed Research International. 2016;2016:6. doi: 10.1155/2016/9262909.9262909
Source: PubMed